School of Medicine

Wayne State University School of Medicine

Jing Li

 

Jing Li, Ph.D.
Associate Professor
Director, Pharmacology Core
Karmanos Cancer Institute
Department of Oncology
Wayne State University School of Medicine
4100 John R, HWCRC/Room 523
Mail Code: HW05AO
Detroit, MI 48201
Phone: 313-576-8258
Email: lijin@karmanos.org

Research Interests:

  • Clinical pharmacology of anticancer drugs
  • Quantitative pharmacology: population (nonlinear mixed effects) pharmacokinetic-pharmacodynamic modeling; physiologically-based pharmacokinetic modeling/simulation
  • Pharmacometabolomics

Research Description:
The central theme of my research is to promote rational cancer therapy and drug development by better understanding the clinical pharmacology of anticancer agents, that is, how they behave in patients.  My research spans key areas of clinical pharmacology, including pharmacokinetics (PK) – the study of drug absorption, distribution, metabolism, and elimination; pharmacodynamics (PD) – the study of drug effects; pharmacogenetics – the study of genetic determinants of drug disposition and response; and recently pharmacometabolomics – the study of metabolic profile changes in response to drug treatment.

Anticancer drugs exhibit large interindividual PK/PD variability that can lead to therapeutic failure or severe toxicity.  One focus of my research is to elucidate the mechanisms underlying this variability, using an interactive in vitro-in silico-in vivo approach that is involved in vitro drug metabolism and transporter studies, modeling and simulation, and clinical studies.  Another focus of my research is quantitative pharmacology using population PK/PD modeling and physiologically-based pharmacokinetic modeling/simulation approaches to characterize and predict the PK, PD, and PK-PD relationships of anticancer drugs in a quantitative manner.  A better understanding of the underlying causes of PK/PD variability and the establishment of PK-PD relationships between the dose/schedule, exposure, and effects (efficacy or toxicity) will have significant impact on rational drug development and optimal cancer therapy.

Selected Publications:

Li J, Kim S, Shields AF, Douglas KA, McHugh CI, Lawhorn-Crews JM, Wu J, Mangner TJ, LoRusso PM.  Integration dynamic positron emission tomography and conventional pharmacokinetic studies to delineate plasma and tumor pharmacokinetics of FAU, a prodrug bioactivated by thymidylate synthase.  J Clin Pharmacol. 2016 Apr 20. [Epub ahead of print]

Wu J, Zhang Y, Wiegand R, Wang J, Bepler G, Li J.  Quantitative analysis of intracellular nucleoside triphosphates and other polar metabolites using ion pair reversed-phase liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 2015;1006:167-78.

Wu J, Shaw J, Dubaisi S, Valeriote F, and Li J.  In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radio-protective agent.  Drug Metab Dispos 2014;42:2058-67.

Li J, Kim S, Sha X, Wiegand R, Wu J, and LoRusso P.  Complex disease-, gene-, and drug-drug interactions: impact of renal function, CYP2D6 status, and OCT2 activity on the pharmacokinetics of veliparib.  Clin Cancer Res 2014;20:3931-44.

Wu J, LoRusso P, Matherly L, Li J.  Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097.  Clin Cancer Res. 2012;18: 2066-79.

Zheng Q, Sha X, Liu J, Heath E, LoRusso P, Li J.  Association of human cytochrome P450 1A1 (CYP1A1) and sulfotransferease 1A1 (SULT1A1) polymorphisms with differential metabolism and cytotoxicity of aminoflavone.  Mol Cancer Ther 2010;9:2803-13.

Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, LoRusso P.  Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients.  J Clin Pharmacol 2009;49:1467-76.

Li J, Jameson MB, Baguley BC, Pili R, Baker SD.  Population pharmacokinetic-pharmacodynamic (PK-PD) model of the vascular-disrupting agent 5,6-dimethylxantheone-4-acetic acid (DMXAA) in cancer patients.  Clin Cancer Res 2008;14:2102-10.

Li J, Zhao M, He P, Hidalgo M, and Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P-450 enzymes.  Clin Cancer Res 2007;13:3731-37.

Li J, Karlsson MO, Brahmer J, Sparreboom A, Zhao M, Hidalgo M, and Baker SD.  CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.  J Natl Cancer Inst 2006;98:1714-23.

Complete List of Publications in My Bibliography:

http://www.ncbi.nlm.nih.gov/sites/myncbi/1JCXa3CUJiCAB/bibliography/47188821/public/?sort=date&direction=ascending

Other Links:

http://www.karmanos.org/pharm

http://www.oncology.med.wayne.edu/profile.php?id=90397

Education and Training:
Ph.D., Pharmaceutical Sciences (2003): National University of Singapore, Singapore
Post-doctoral Fellow, Clinical Pharmacology (2006): Johns Hopkins University, Baltimore, MD

Cancer Biology Courses Taught:
CB7240 Principles of Cancer Therapy
CB7990 Research Technologies in Cancer Research